AGENUS INC

Armen Garo H’s 2026 stock‑option purchase shows insider confidence in Agenus’ checkpoint‑antibody platform, hinting at future upside and a strong incentive‑aligned strategy.

Timothy Wright’s new insider option purchase shows Agenus’s confidence in its oncologic pipeline and upcoming ROBBIN trial—potential upside for investors if milestones hit.

Insider purchase by Dr. Armen Garo H fuels confidence in Agenus Inc. (AGUS) as the company pivots toward its high‑potential ROBBIN Phase 3 trial, private placement, and AI‑driven oncology strategy.

Insider buying at Agenus signals confidence in its EGFR‑targeted pipeline, showing potential upside for investors while highlighting the need to monitor cash burn.

CEO insider buying signals confidence in Agenus Inc. (AGNS) – a niche immuno‑oncology and RSV vaccine firm trading at a deep discount, poised for upside after Arexvy approval.

Insider confidence surges as Agenus executives buy options—signals optimism ahead of Phase III data, potentially boosting the immuno‑oncology stock.

Dr. Armen Garo’s latest insider purchase of over 3,400 Agenus shares—at $3.91 each—underscores management confidence in the company’s immuno‑oncology pipeline and long‑term upside potential for investors.

Wright Timothy’s recent purchase of 2,448 deferred stock units signals strong insider confidence in Agenus Inc., offering investors a nuanced view of governance, valuation, and the company’s immuno‑oncology prospects.

Insider buying fuels optimism for Agenus’s TCR therapy and bispecific platform, highlighting potential growth amid FDA milestones and partnership upside.

CEO insider buys 4,829 Agenus shares, signaling confidence in the company’s immuno‑oncology pipeline and potential upside for investors.